9.645

4.41% -0.355

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $9.645, with a volume of 18,263. It is down -4.41% in the last 24 hours and down -20.34% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Previous Close:

$10.00

Open:

$10

24h Volume:

18,263

Relative Volume:

0.19

Market Cap:

$252.10M

Revenue:

$26.00M

Net Income/Loss:

$-219.71M

P/E Ratio:

-0.1937

EPS:

-49.8

Net Cash Flow:

$-51.37M

1W Performance:

+4.36%

1M Performance:

-20.34%

6M Performance:

-49.24%

1Y Performance:

-69.60%

1-Day Range:

$9.36

$10.02

1-Week Range:

$8.46

$10.10

52-Week Range:

$8.46

$41.87

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	9.715	237.35M	26.00M	-219.71M	-51.37M	-49.80
ONC Beone Medicines Ltd Adr	246.59	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.68	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.32	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	80.89	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	493.00	64.44B	14.09B	4.50B	2.96B	39.28

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Initiated	BTIG Research	Buy
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

01:03 AM

Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study - marketscreener.com

01:03 AM

07:34 AM

RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | R - GuruFocus

07:34 AM

07:28 AM

Cartesian Therapeutics Announces First Participant Enrolled in t - GuruFocus

07:28 AM

07:12 AM

Cartesian Therapeutics Initiates Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis - Nasdaq

07:12 AM

07:01 AM

Cartesian Therapeutics Announces First Participant Enrolled - GlobeNewswire

07:01 AM

07:00 AM

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - Yahoo Finance

07:00 AM

May 27, 2025

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga

May 27, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust Corp - Defense World

May 27, 2025

May 22, 2025

Q1 Earnings Forecast for RNAC Issued By HC Wainwright - Defense World

May 22, 2025

HC Wainwright Has Bearish Forecast for RNAC Q2 Earnings - Defense World

May 22, 2025

May 20, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

May 20, 2025

May 19, 2025

Multiple Myeloma Pipeline 2025: Groundbreaking Clinical - openPR.com

May 19, 2025

May 15, 2025

Cantor Fitzgerald Comments on RNAC FY2025 Earnings - Defense World

May 15, 2025

May 13, 2025

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - The Manila Times

May 13, 2025

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ... - Eagle-Tribune

May 13, 2025

Wells Fargo & Company MN Acquires 2,568 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 13, 2025

May 12, 2025

Cartesian Therapeutics (RNAC) Poised for Growth with Strong Phas - GuruFocus

May 12, 2025

May 11, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

May 11, 2025

Barclays PLC Buys 7,488 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 11, 2025

May 10, 2025

MetLife Investment Management LLC Invests $119,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

May 10, 2025

Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 10, 2025

Needham & Company LLC Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World

May 10, 2025

May 09, 2025

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC) - The Globe and Mail

May 09, 2025

Cartesian Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025

May 08, 2025

Needham Maintains Buy Rating on RNAC, Lowers Price Target | RNAC Stock News - GuruFocus

May 08, 2025

RNAC Reports Strong Q1 Revenue Exceeding Expectations | RNAC Stock News - GuruFocus

May 08, 2025